The Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) Study

Uwe Querfeld(Charité - Universitätsmedizin Berlin), Ali Anarat(Cukurova University), Aysun Karabay Bayazıt(Cukurova University), Ayşı̇n Bakkaloğlu(Hacettepe University), Yelda Bilginer(Hacettepe University), Salim Çalışkan(Istanbul University-Cerrahpaşa), Mahmut Çivilibal(Istanbul University-Cerrahpaşa), Anke Doyon(University Hospital Heidelberg), Ali Düzova(Hacettepe University), Daniela Kracht(Medizinische Hochschule Hannover), Mieczysław Litwin(Children's Memorial Health Institute), Anette Melk(Medizinische Hochschule Hannover), Sevgı Mır(Ege University), Betül Sözeri(Ege University), Rukshana Shroff(University College London), René Zeller(Charité - Universitätsmedizin Berlin), Elke Wühl(University Hospital Heidelberg), Franz Schaefer(University Hospital Heidelberg)
Clinical Journal of the American Society of Nephrology
June 25, 2010
Cited by 137Open Access
Full Text

Abstract

BACKGROUND AND OBJECTIVES: Children and adolescents with chronic kidney disease (CKD) are at high risk for cardiovascular morbidity and mortality. A systemic arteriopathy and cardiomyopathy has been characterized in pediatric dialysis patients by the presence of morphologic and functional abnormalities. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Cardiovascular Comorbidity in Children with CKD (4C) Study is a multicenter, prospective, observational study aiming to recruit more than 600 children, aged 6 to 17 years, with initial GFR of 10 to 45 ml/min per 1.73 m(2). The prevalence, degree, and progression of cardiovascular comorbidity as well as its association with CKD progression will be explored through longitudinal follow-up. The morphology and function of the heart and large arteries will be monitored by sensitive noninvasive methods and compared with aged-matched healthy controls. Multiple clinical, anthropometric, biochemical, and pharmacologic risk factors will be monitored prospectively and related to the cardiovascular status. A whole-genome association study will be performed to identify common genetic variants associated with progression of cardiovascular alterations and/or renal failure. Monitoring will be continued as patients reach end-stage renal disease and undergo different renal replacement therapies. RESULTS: While cardiovascular morbidity in adults is related to older age and additional risk factor load (e.g., diabetes), the role of CKD-specific factors in the initiation and progression of cardiac and vascular disease are likely to be characterized with greater sensitivity in the pediatric age group. CONCLUSIONS: The 4C study is expected to provide innovative insight into cardiovascular and renal disease progression in CKD.


Related Papers

No related papers found

Powered by citation graph analysis